Pierre Fabre Oral Care and BMG PHARMA S.r.l sign a Distribution and Supply Agreement for AFTACURE Gel and AFTACURE Spray
May 15, 2017
Pierre Fabre Pharmaceuticals, the second-largest French private pharmaceutical laboratory, and BMG Pharma S.r.l., an Italian innovative specialty pharmaceutical company, announce the signature of an International Distribution and Supply Agreement for two BMG original oral and dental hygiene products: Aftacure Gel and Aftacure Spray.
Under the terms of the agreement, the Pierre Fabre Oral Care brand (PFOC) of Pierre Fabre Pharmaceuticals will get the rights to distribute and commercialize Aftacure Gel and Aftacure Spray under its trademark “Elgydium Clinic” in different territories worldwide. Pierre Fabre Oral Care already benefits from a strong recognition from dentists, hygienists and pharmacists, as well as from expert learned societies worldwide. Aftacure Gel and Aftacure Spray will expand their range of products in these countries and strengthen their position.
We have a strong position in Europe and one of our commitment is to provide the markets with the best and most comprehensive ranges of Oral and Dental Hygiene products. We therefore rely on our dedicated R&D team to launch innovative products, but we also develop partnerships with specialized companies to pool our skills. This agreement with BMG Pharma illustrates this open innovation strategy and our will to complete our offer. said Pascal Lefrançois, Head of Pierre Fabre Consumer Health Care.
We are very proud to cooperate with Pierre Fabre Oral Care, a brand of Pierre Fabre Consumer Health Care, one of the leading pharmaceutical company in Europe which recognized the value and novelty of our products - said Marco Mastrodonato, CEO of BMG Pharma S.r.l. - We are very pleased to offer our products Aftacure Gel and Aftacure Spray, which under Pierre Fabre’s knowledge and experience will reach a large number of patients allowing them to receive fast pain relief for mouth lesions. This partnership is a major milestone for BMG as it allows our company to enlarge its market opportunity in the pharmaceutical world.